Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases.
There are currently five Nanobodies® in clinical development.
Jefferies 2013 Global Healthcare Conference
3-6 June – New York (NY), USA
Shareholders Clubs @ Ablynx (Dutch only)
18th September at 5.45pm
11th December at 5.45pm
To attend an event, please register via email: , mentioning your name and preferred day. The registrations are on a “first come, first serve” basis.
Past events & presentations
Ablynx reported excellent interim results from Phase I/II study with its anti-IL-6R Nanobody, ALX-0061, in rheumatoid arthritis patients – 4 October 2012
webcast replay – pdf version of the presentation